Learn from the past?25 Jul 2022 19:46
The following is an *opinion* based on observation of previous behaviour by 88E management. I offer a possible explanation for 88E SP weakness in the short term.
1) The most obvious answer is that the wider market, despite the best efforts of fact-resistant posters on this forum, has realised PANR is cheaper on a risk/return basis than 88E. My arguments on this front are well-rehearsed: differential in scale, quality and quantity of empirical data from 3D and drilling results, finance in place v's insufficient finance, quality of corporate governance, currently operational v's 2023, etc, etc.
2) I think (hope?) there is a consensus view based on the most recent Q2 financial report that 88E will have to a) undertake a highly dilutive capital raise b) give up a significant slice of Icewine East or c) both a + b in order to finance a drill in Icewine East at some point in 2023.
Let's place ourselves in management's shoes. There was c.US$7.25m on the b/s at the end of Q2 with some more bills to pay for Merlin-2; the ongoing cost of licensing 3D seismic (which outrageously has still not been communicated in full to shareholders)l; ongoing G&A and leasing fees offset by the income from Longhorn. Either which way, there is not a snowball's chance that 88E can self-fund Icewine-3 in 2023 in the current situation. All agreed?
So, do they wait for the data to start arriving from PANR's Alkaid-2 and then launch a fundraise off the back of any publicity generated? Or is that too much of a risk, and the overwhelming and primary role of the BoD/MD/FD is to ensure the company is funded no matter what? I submit that some shareholders have voted with their feet and decided to sell because they suspect the company will be readying for a cash raise some time soon.
To be clear, I have no idea what path management will choose. But they are going to have to make a choice. even deciding to wait for the data to arrive from PANR's Alkaid-2 is a "decision".
I submit readers of this forum are facing a similar choice, with one meaningful exception. Yes, shareholders can decide to sell because they don't wish to be diluted further (and if 88E is to *self-finance* Icewine-3 we're talking about a minimum of US$30m IMO) but that will mean losing exposure to the shared asset over the period when news, good or bad, arrives from Alkaid-2. There is a possible solution. Selling 88E to remove oneself from the risk of dilution but to invest that capital to buy shares in the ***funded*** co-owner of the asset. In so doing, an investor keeps exposure to the same asset but reduces the funding risk.
I repeat, the minute Dave Wall stated formally 88E and PANR share an asset, these types of compare'n'contrast exercises become essential and utterly standard for equity analysts. Fact.